Publication Name	World Journal of Gastroenterology
Manuscript ID	116467
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy
Manuscript Source	Invited Manuscript
All Author List	Sheng Xu, Zheng Zhu, Pei-Hong Shi, Yue-Ting Xu, Hui-Ming Zhang, Yang Zheng, Yi-Tong Chen, Guang-Rong Lu and Bin-Jiao Zheng
Funding Agency and Grant Number	Funding Agency Grant Number Zhejiang Medical and Health Science and Technology Plan Project 2023KY910 Project of Special Research Funds for Clinical Medicine of Zhejiang Medical Association 2023ZYC-A124
Corresponding Author	Bin-Jiao Zheng, PhD, Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, University Town, Chashan, Wenzhou 325000, Zhejiang Province, China. gusdy13x@wmu.edu.cn
Key Words	Gastric cancer; N6-methyladenosine; Cyclic guanosine monophosphate-protein kinase G; Molecular markers; IGF2BP3; FBXO32
Core Tip	Gastric cancer (GC) needs more precise therapies, and Si et al’s study presents promising insights by revealing that the N6-methyladenosine (m6A) reader IGF2BP3 drives GC progression through an m6A-dependent post-transcriptional mechanism. This fills the long-standing gap in understanding the downstream targets of IGF2BP3 in GC and, for the first time, links the IGF2BP3/FBXO32 axis to the cyclic guanosine monophosphate-protein kinase G pathway. Additionally, it promotes discussions on the role of m6A in tumorigenesis and points to critical directions such as mechanistic exploration, tumor microenvironment crosstalk and subtype-specific research, laying key groundwork for translating this axis into GC clinical treatment.
Citation	Xu S, Zhu Z, Shi PH, Xu YT, Zhang HM, Zheng Y, Chen YT, Lu GR, Zheng BJ. Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy. World J Gastroenterol 2026; In press

Received	2025-11-12 02:13
Peer-Review Started	2025-11-12 02:13
First Decision by Editorial Office Director	2026-01-09 10:10
Return for Revision	2026-01-09 10:10
Revised	2026-01-22 11:39
Publication Fee Transferred
Second Decision by Editor	2026-02-06 02:54
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-02-06 09:44
Articles in Press	2026-02-06 09:44
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com